Preferential Issue. face value of ₹ 10/- each pursuant to the conversion of 51,00,000 Fully Convertible…
As filed · Conversion
CapitalWatchNotablemateriality 71 out of 100
What happened
FactThe Preferential Issue. face value of ₹ 10/- each pursuant to the conversion of 51,00,000 Fully Convertible Warrants (“Warrants”), allotted. on August 30, 2024, at an issue price of ₹ 121/- each to Essix Biosciences Limited, belonging to Promoter & Promoter.
Why it matters
CapitSignal interpretationShares are issued to named investors at a set price, diluting existing holders and changing who sits on the register.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
DelayedEarlierQ1 FY27
In the second quarter we are expecting a major push from Arrotex on that Macrogol new molecule which we launched.
NowQ1 FY27
And in third and fourth quarter we see a lot of progress coming from Ibuprofen and Clarithromycin granules.
Change
FactTimeline delay
Implication
CapitSignal interpretationThe earlier statement expected a major push in the second quarter, while the current statement indicates progress is now anticipated in the third and fourth quarters.confidence 90%
Watch next
Fact- Who the allottees are
- Issue price versus market price
- Lock-in period on the new shares
- We expect FY27 to witness revenue growth of more than 50%. (management committed by FY27)
- A key milestone was the commercialization of the Viatris (USA), Manx (UK) and Arrotex (Australia) CDMO partner (management committed by FY27)
Evidence
- Ind-Swift Laboratories Limited has informed the Exchange about Conversion(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- PREFERENTIAL_ALLOTMENT base 66; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%